News coverage about Selecta Biosciences (NASDAQ:SELB) has been trending somewhat negative this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Selecta Biosciences earned a news impact score of -0.04 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.2618832828201 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Selecta Biosciences, Inc. (NasdaqGM:SELB)’s Target Weight Reaches 0.02320 as Profit Growth Hits 0.30224 (baycityobserver.com)
- 50 days simple moving average (SMA50) under Consideration: BlackRock 2022 Global Income Opportunity Trust … (stocksnewspoint.com)
- Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology … (nasdaq.com)
- Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR) (finance.yahoo.com)
SELB stock traded up $0.54 during midday trading on Wednesday, reaching $14.07. 6,146 shares of the company traded hands, compared to its average volume of 83,253. Selecta Biosciences has a 52-week low of $7.95 and a 52-week high of $24.02. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. The company has a market cap of $303.69 million, a PE ratio of -4.36 and a beta of -3.43.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 150.84%. equities research analysts expect that Selecta Biosciences will post -3.13 EPS for the current year.
A number of equities analysts recently commented on the company. ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, July 5th. Janney Montgomery Scott assumed coverage on Selecta Biosciences in a research note on Wednesday, June 27th. They set a “buy” rating and a $33.00 price target for the company. Zacks Investment Research lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Canaccord Genuity reissued a “buy” rating and set a $40.00 price target on shares of Selecta Biosciences in a research note on Thursday, June 28th. Finally, BidaskClub lowered Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $28.25.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: Stock Symbol
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.